Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Protalix BioTherapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 388,000 11.24M 2.97M 34.42M 11.51M
Cost of Goods Sold (COGS) incl. D&A 8.3M 7.11M 4.94M 8.14M 5.43M
COGS excluding D&A 6.38M 4.02M 1.31M 4.45M 1.89M
Depreciation & Amortization Expense 1.92M 3.09M 3.62M 3.69M 3.54M
Depreciation 1.92M 3.09M 3.62M 3.69M 3.54M
Amortization of Intangibles 0 0 0 0 0
Gross Income (7.91M) 4.14M (1.97M) 26.28M 6.09M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 23.99M 29.07M 34.55M 37.45M 40.7M
Research & Development 19.84M 22.5M 27.99M 28.69M 33.31M
Other SG&A 4.15M 6.57M 6.57M 8.76M 7.39M
Other Operating Expense 0 4.99M 0 0 0
Unusual Expense 67,000 43,000 10,000 1M 1M
EBIT after Unusual Expense (67,000) (43,000) (10,000) (1M) (1M)
Non Operating Income/Expense 67,000 0 0 0 8.5M
Non-Operating Interest Income 462,000 968,000 2,000 554,000 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 674,000
Gross Interest Expense 0 0 0 0 674,000
Interest Capitalized 0 0 0 0 0
Pretax Income (31.44M) (29M) (36.53M) (11.62M) (27.79M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (31.44M) (29M) (36.53M) (11.62M) (27.79M)
Minority Interest Expense 0 0 0 0 0
Net Income (31.44M) (29M) (36.53M) (11.62M) (27.79M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (31.44M) (29M) (36.53M) (11.62M) (27.79M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (31.44M) (29M) (36.53M) (11.62M) (27.79M)
EPS (Basic) (0.41) (0.36) (0.43) (0.13) (0.30)
Basic Shares Outstanding 76.94M 80.96M 84.65M 90.85M 92.37M
EPS (Diluted) (0.41) (0.36) (0.43) (0.13) (0.30)
Diluted Shares Outstanding 76.94M 80.96M 84.65M 90.85M 92.37M
EBITDA (29.98M) (26.83M) (32.9M) (7.48M) (31.07M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.